Análisis Argos
PTEN
PTENBarata · ojo al riesgo
Patterson-UTI Energy, Inc. · Energy
US$ 8.66
precio al 2026-07-04
Valor justo Argos*
US$ 10–11
vs. su valor justo
21% por debajo
Score Argos
40/100
Barata · ojo al riesgo
LA RESPUESTA
El mercado la precia para que se encoja 4.8% al año — menos de lo que viene demostrando (2.4%). Un negocio de calidad castigado por expectativas pesimistas: por eso está entre las llamadas de Argos. Ojo: tiene señales de riesgo en sus números — es barata con asterisco.
Recompensas
Cotiza por debajo de su valor justo: el mercado le pide menos crecimiento del que viene demostrando.
Reparte dividendo sostenible (4.16%).
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
VALOR4/6FUTURO3/6PASADO1/6SALUD2/6DIVIDENDO5/6
El Iris de calidad
VALOR4/6FUTURO3/6PASADO1/6SALUD2/6DIVIDENDO5/6
ValorCotiza por debajo de su valor justo
FuturoCrecimiento moderado
PasadoHistorial débil
SaludBalance razonable
DividendoDevuelve capital al accionista
Score Argos40de 100Barata · ojo al riesgo
Ingresos10%
US$ 4.8 B
Margen operativo97%
-0.5%
Flujo de caja libre26%
US$ 0.4 B
Deuda neta
US$ 0.9 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 3.3B
P/E
EV/EBITDA4.5x
FCF yield11.3%
ROIC-0.6%
Margen operativo-0.5%
Crecim. ingresos-10.3%/año
Piotroski F5/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

seekingalpha.com · 1 jul
Patterson-UTI Energy Inc: Consider Holding On To This Oil Drilling Company As The Strait Of Hormuz Reopens
Patterson-UTI Energy, Inc. (PTEN) is rated a hold due to short-term oil price volatility and long-term demand uncertainty. PTEN's Q1 2026 revenue declined 12.75% YoY, with negative net income in six of the last seven quarters. DCF analysis implies a $27.08 intrinsic value per share, but near-term oil price declines suggest PTEN will likely remain below $11 in the next year.
businesswire.com · 12 jun
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US Food and Drug Administration (FDA)-authorized test.1 The approval by the US FDA was bas.
zacks.com · 11 jun
Patterson-UTI (PTEN) is a Great Momentum Stock: Should You Buy?
Does Patterson-UTI (PTEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
accessnewswire.com · 5 jun
Patterson-UTI Reports Drilling Activity for May 2026
HOUSTON, TX / ACCESS Newswire / June 5, 2026 / PATTERSON-UTI ENERGY, INC. (NASDAQ:PTEN) today reported that for the month of May 2026, the Company had an average of 92 drilling rigs operating in the United States.
zacks.com · 2 jun
Is PattersonUTI Energy (PTEN) Outperforming Other Oils-Energy Stocks This Year?
Here is how Patterson-UTI (PTEN) and Ring Energy (REI) have performed compared to their sector so far this year.
gurufocus.com · 27 may
Patterson-UTI Energy Inc (PTEN) Shares Fall 5.3% -- What GF Score of 56 Tells Investors
On May 27, 2026, Patterson-UTI Energy Inc (PTEN) shares fell 5.3% to a current price of $11.48. The stock has experienced a 52-week range from $5.10 to $13.08,
fool.com · 27 may
Sourcerock Group Adds to Patterson-UTI Energy Stake, According to Recent SEC Filing
Patterson-UTI turns producer spending into rigs, completion work, and wellsite services. The focus for investors is whether high fleet utilization is becoming pricing power and free cash flow after a quarter that still ended in a loss.
zacks.com · 27 may
3 Oil & Gas Drilling Stocks With Strong Upside Potential
Following a careful analysis of the Zacks Oil and Gas - Drilling industry, we advise focusing on companies like PTEN, HP and NBR.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.